TAP INTO A NEW POSSIBILITY for mental health

Now FDA-Cleared as an Add-on Therapy for Ages 15 and Older!
This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.

Certain statements in this presentation and accompanying commentary that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "outlook," "potential," "believe," "expect," "plan," "anticipate," "predict," "may," "will," "could," "would" and "should" as well as the negative of these terms and similar expressions. These statements include those relating to the Company's business outlook and current expectations for upcoming quarters and fiscal year 2024, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of public health crises on the Company's operations, manufacturing and supply chain interruptions or delays; the Company's ability to execute its business strategy; the Company's ability to achieve or sustain profitable operations due to its history of losses; the Company's reliance on the sale and use of its NeuroStar Advanced Therapy system to generate revenues; the scale and efficacy of the Company's salesforce; the Company's ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company's products; physician and patient demand for treatments using the Company's products; developments in competing technologies and therapies for the indications that the Company's products treat; product defects; the Company's ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy system for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; our ability to successfully roll-out our Better Me Guarantee Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow break-even in the fourth quarter of 2024 and on a full-year basis in 2025. For a discussion of these and other related risks, please refer to the Company's recent filings with the U.S. Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this presentation. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events, or changes in the Company's expectations.
## Presenters

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Keith Sullivan</strong></td>
<td>President &amp; Chief Executive Officer</td>
</tr>
<tr>
<td><strong>Steve Furlong</strong></td>
<td>Executive Vice President, Chief Financial Officer &amp; Treasurer</td>
</tr>
</tbody>
</table>

**38+ years of experience**

**37+ years of experience**

[neurostar.com](http://neurostar.com)
NeuroStar is Renewing Lives by Transforming Neurohealth

We’re inspired every day by the opportunity to help people live more fulfilling lives

Market Leader in TMS
#1 Physician recommended with over 6.4 million treatment sessions performed in over 175,000 patients

Robust R&D Pipeline
3rd generation system. Largest clinical dataset in the world to drive new indications

Dedicated to Practice Success
Largest direct sales and customer support team in the industry to support over 1,100 U.S. offices

Widely Reimbursed
Dedicated to driving health policy to ensure broad US reimbursement among commercial and government payors

1 Data on file, Neuronetics, Inc.
Over 29 Million People Can Benefit from NeuroStar TMS

Total Available Market

29.3 million

U.S. Adults and Adolescents (ages 15-21) suffering from depression, depression with anxiety, and OCD

Nearly 8 million patients are poorly served by antidepressant medication

- Lack of Treatment Efficacy
- Intolerable Side Effects

<table>
<thead>
<tr>
<th>Condition</th>
<th>Suffering</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult Depression (MDD)</td>
<td>21 million</td>
<td>6.4 million</td>
</tr>
<tr>
<td>Adolescent Depression</td>
<td>4.3 million</td>
<td>1 million</td>
</tr>
<tr>
<td>Anxious Depression</td>
<td>53% of MDD patients have significant anxiety</td>
<td></td>
</tr>
<tr>
<td>OCD</td>
<td>4 million</td>
<td>235K</td>
</tr>
</tbody>
</table>

Lack of Treatment Efficacy
Intolerable Side Effects

8 million patients are poorly served by antidepressant medication

New indication: 35% increase in addressable market

2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration
4. Depression - Pharma Intelligence Disease Analysis, www.datamonitorhealthcare.com, Publication Date: June 2021
5. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health
8. Definitive Health Diagnosis/Prescription Data: 03/25/22
More Medication Isn’t the Answer

With every new medication, adult MDD patients try\textsuperscript{1-4}:

The chances of feeling better go down

And the likelihood of stopping medication because of side effects goes up

1. Trivedi (2006), Am J Psychiatry
Only NeuroStar TMS has…
Proven, Long-Term Relief for Adult Depression

Real-World Clinical Results for Patients with MDD

- 83% Improvement in depression symptoms
- 62% Symptom relief (remission)

Clinically Proven Durability through 12 Months

NeuroStar Clinical Excellence Validated by Extensive Research and Publications

Most Widely Published in TMS
- 15 studies leading to FDA clearance
- 31+ peer-reviewed publications demonstrates clinical safety and efficacy

Investigator Initiated Studies
- Expands understanding of TMS and its potential clinical applications
- 65+ studies with 1,900+ patients
Only NeuroStar … 
Delivers Consistent, Repeatable Treatment for Optimal Outcomes

Contact Sensing with Real-Time Feedback
Proprietary to NeuroStar

- Continuous Monitoring
  Ensures the prescribed dose is delivered every time

Precise Coil Placement – NeuroSite™
Proprietary to NeuroStar

- Good Contact
- Consistent Coil Placement
- Faster Patient Setup with Fewer Steps
- Reproducible Patient Setup
Proprietary TrakStar Platform Provides Actionable Insights for NeuroStar and its Practices

World’s Largest Depression Outcomes Registry\(^1\) Contributes to Future Indications and Publications

- 175,000+ Total NeuroStar patients treated worldwide
- 17,175+ Total Outcomes Registry patients

Patient Management Database and Reporting System

- Tools to identify more patient candidates (PHQ-10, Benefits Investigations)
- Automated tools to efficiently manage the patient journey

1. Neuronetics, Inc. internal data on file 2024.
NeuroStar Has the Largest Issued Patent Portfolio of All TMS Companies…

Patent Portfolio

- **33 US / 51 OUS**
  Issued or allowed patents
- **10 US / 7 OUS**
  Pending patent applications

Contact Sensing

- U.S. patent

MT Assist

- U.S. patent

Iron Core Magnet

- U.S. patent

...protecting our technical advantage and ensuring freedom to operate globally
**NeuroStar: The Unrivaled TMS Solution**

<table>
<thead>
<tr>
<th>Feature</th>
<th>NeuroStar</th>
<th>BraisWay</th>
<th>magstim</th>
<th>MagVenture</th>
<th>CLOUDTMS</th>
<th>Nexstim</th>
<th>NoTecore</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-cleared for iTBSTheta Burst</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>FDA-cleared for OCD</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Publications from Depression Registration Trials</td>
<td>12</td>
<td>1</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>FDA-cleared for Anxious Depression</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Practice Consultants</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>FDA-cleared for Adolescent Depression</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Marketing including DTC Advertising</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Contact Sensing</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>World’s Largest MDD Outcomes Registry</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

* Additional hardware purchase required
Now FDA-Cleared as a First-Line, Adjunct Treatment for Ages 15 and Older

NEW: FDA-Cleared March 22, 2024
Treating Adolescent Depression Had Two Choices…

Until Now

Youth Depression is On the Rise

- Nearly 1 in 5 US adolescents experience at least one major depressive episode each year¹
- Mental health concerns top parents’ list of worries, even above children’s physical safety²

Limited Options for Adolescents

- Only 2 antidepressants are FDA-approved for use in adolescents: Prozac (fluoxetine) and Lexapro (escitalopram)³
- The FDA has issued a “black box” warning indicating the use of these drugs to treat MDD in adolescents may increase the risk of suicidal ideations and behaviors⁴

As the Market Leader, NeuroStar is Revolutionizing Mental Health with New Adolescent Indication

1

1st and Only to Market

NeuroStar is the only FDA-cleared TMS treatment for adolescent depression

1st Line Treatment

For adolescents, NeuroStar can be used as an add-on treatment, without prior medication failures
TrakStar® Real-World Data Demonstrates Improvement in Adolescent Depression Severity

78% Improvement in depression symptoms

48% Symptom relief (remission)

Real-world data was collected through NeuroStar’s proprietary TrakStar® platform, saving valuable time and money.

Results analyzed from a subset with available CGI-S data demonstrated a 78% response rate and 48% remission rate, while PHQ-9 demonstrated 59.4% response and 30.0% remission respectively. Patients had an average 10+ point improvement in their depression symptoms when using the PHQ-9.
New Opportunity with Adolescent Psychiatrists

New Customers

- Expanded opportunity
  - 8,000+ adolescent and child psychiatrists
  - 6,000 adolescent psych nurse practitioners

Supported by 17 Capital Sales Representatives

1,100+ Existing Customers

- Increases the value of NeuroStar system by broadening label to additional patients
- 50% of customers treated adolescents 15-21 in past year
- Increase awareness and education among adolescents and highly motivated parents through digital, social media, and mass media outreach

Supported by 45 Practice Development Managers

Sales force size remains the same
2024 Adolescent Marketing Strategy Focused on Parents and Practices

Key Messages
Treats depression at the source | Non-drug, non-invasive | Proven safe and effective

Outside the Practice
Parent Awareness & Education

Inside the Practice
Practice Tools & Education
The Largest Direct Sales and Customer Support Team¹

Experienced team dedicated to consistent growth and practice success

1. Neuronetics, Inc. internal data on file 2024.
NeuroStar STARS SOLUTION
Proven Program for Ongoing Practice Success

Start

- REIMBURSEMENT
- CONSULTING
- TRAKSTAR 1.0
- PHQ-10
- NEUROSTAR TREATMENT ROOM SET UP

Train

- FRONT DESK TRAINING
- CONSULTATION TRAINING
- CLINICAL TRAINING
- TRAKSTAR 2.0

Awareness

- PRACTICE BRANDING
- WEBSITE BRANDING

Reach Your Patients

- PATIENT EMAIL OUTREACH
- PATIENT EDUCATION EVENTS

Source New Patients

- DIGITAL MARKETING
- HCP EDUCATIONAL EVENTS
NeuroStar Better Me Provider Program is designed to lead the industry in standards for patient care.

Providers are required to:

The Result:

3.6x more MTs in Better Me Providers vs. non-Better Me Providers¹

* Clinical evidence demonstrates superior outcomes for patients who complete a course of NeuroStar therapy compared to those who do not complete treatment. However, the actual number of sessions performed is subject to the medical judgment of the prescribing physician. The number of treatment sessions performed is not a selection criteria for entry into the Better Me Guarantee Program and will not be used as a basis to remove a provider from the program. | ¹. Data on file, Neuronetics, Inc.
Better Me Providers are Quickly Addressing Interested Patients in Need

5x Faster
from potential patient interest to MT

<table>
<thead>
<tr>
<th>Q1 2023</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>82 days</td>
<td>17 days</td>
</tr>
</tbody>
</table>

All patient interest in Local Consumable Offices; Phase 2: Feb 1, 2024 – Apr 7, 2024 vs. PY
NeuroStar University Optimizes Clinical Outcomes and Practice Efficiency

58% Greater Treatment Session Utilization Among NSU Attendees

2-DAY COURSE AT OUR STATE-OF-THE-ART TRAINING CENTER

Practices learn through a combination of instruction and peer-to-peer learning.

NSU Utilization Performance Index
Baseline index values are based on January 2022 utilization. Excludes new sites from Classes 2022 and 2023.

Practices that attend NSU consistently outperform practices that do not on a month-to-month basis. In March 2024, NSU practices performed 58% better over baseline Jan 2022 data, than sites that have not attended NSU.
Only NeuroStar Invests in Co-Op Marketing to Build Local Consumer Awareness

**Co-Op Marketing:** collaborative effort with practices to increase local patient awareness while sharing advertising costs

- **+15%** treatment session utilization*
- **+16%** in new MTs*

* Data on file, Neuronetics, Inc.
NeuroStar is Available at the Largest National Mental Health Centers

<table>
<thead>
<tr>
<th>greenbrook gb TMS NeuroHealth Centers</th>
<th>Southern California TMS CENTER</th>
<th>Transformations Care Network</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLEVIANt HEALTH CENTERS™ Heal Pain. Restore Hope. Regain Purpose.</td>
<td>LifeStance HEALTH</td>
<td>Z-C TMS</td>
</tr>
<tr>
<td>Activepath MENTAL HEALTH: Formerly known as Active Recovery TMS</td>
<td>Elite DNA Therapy Services a comprehensive approach</td>
<td>REFRESH Mental Health</td>
</tr>
</tbody>
</table>
Only NeuroStar is Dedicated to Driving Health Policy to Ensure Broad US Reimbursement

NeuroStar TMS is covered by most national insurance carriers, providing access to more than 300 million people.

NeuroStar also partners with financing companies to provide options for patients whose treatment is not covered by insurance.

1. Neuronetics, Inc. internal data on file 2024.
NeuroStar is the U.S. Market Leader, Opportunity to Continue Expanding Worldwide

Japan Roadmap
- Third largest healthcare spend globally
- Single payor healthcare system
- Shonin approval since 2017
- Exclusive distribution agreement with Teijin Pharma
- Secured national reimbursement listing

Estimated TAM in Japan for Treatment Sessions
- Adults Suffering from MDD 2.4 million
- Treated by a Psychiatrist 655,000
- Failed to achieve remission 475,000
- ~$600 Million Addressable Market
Neuronetics

Management Team

Keith Sullivan
President & CEO

Cory Anderson
SVP, R&D and Clinical

Steve Furlong
EVP, CFO & Treasurer

Rick Grubbs
SVP, National Accounts

Sara Grubbs
SVP, Chief Revenue Officer

Andrew Macan
EVP, GC & Chief Compliance Officer

Rusty Page
SVP, Operations & Quality

Lisa Rosas
SVP, Chief Marketing Officer

Board of Directors

Rob Cascella
Board Chairman

John Bakewell

Joseph Capper

Sheryl Conley

Wilfred Jaeger

Glenn Muir

Megan Rosengarten

Keith Sullivan
Financial Overview
NeuroStar Advanced Therapy for Mental Health
Annual Revenue

Annual Revenue by Geography

- 2021: $53.4, $55.3
- 2022: $63.4, $65.2
- 2023: $69.3, $71.3
- 2024: $78.0-$80.0

Annual Product Revenue (US)

- 2021: $41.9
- 2022: $45.1
- 2023: $50.9
- Guidance: $53.4, $63.4, $69.3

NeuroStar Systems, Treatment Sessions, Other
Q1 2024 Revenue of $17.4M was up 12% from Q1 2023

Guidance ($ in millions)
# Results of Operations

($ in thousands)

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2023</td>
</tr>
<tr>
<td><strong>Revenues</strong></td>
<td>$15,540</td>
</tr>
<tr>
<td><strong>YOY Growth</strong></td>
<td>12%</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>11,396</td>
</tr>
<tr>
<td><strong>Gross Margin</strong></td>
<td>73%</td>
</tr>
<tr>
<td><strong>Operating Expenses:</strong></td>
<td></td>
</tr>
<tr>
<td>Sales and Marketing</td>
<td>11,902</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>77%</td>
</tr>
<tr>
<td>General and Administrative</td>
<td>6,611</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>43%</td>
</tr>
<tr>
<td>Research and Development</td>
<td>2,790</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>21,303</td>
</tr>
<tr>
<td><strong>Loss from Operations</strong></td>
<td>($9,907)</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>-64%</td>
</tr>
</tbody>
</table>
## Financial Position

($ in thousands)

<table>
<thead>
<tr>
<th>($ in thousands)</th>
<th>As of March 31, 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$47,730</td>
</tr>
<tr>
<td>Other Assets</td>
<td>$56,081</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$103,811</strong></td>
</tr>
<tr>
<td>Long-term debt, net</td>
<td>$59,444</td>
</tr>
<tr>
<td>Convertible Preferred Stock Warrant Liability</td>
<td>$0</td>
</tr>
<tr>
<td>Convertible Preferred Stock</td>
<td>$0</td>
</tr>
<tr>
<td>Accumulated Deficit</td>
<td>($383,954)</td>
</tr>
<tr>
<td><strong>Total Stockholders’ Equity</strong></td>
<td><strong>$27,655</strong></td>
</tr>
</tbody>
</table>
Supplemental Information
NeuroStar Advanced Therapy for Mental Health
Local Consumables New MTs (New Patient Starts) & Utilization

Local Consumable Monthly Utilization & New MTs
Jan 2021 - Mar 2024

Utilization
New MT's
### U.S. NeuroStar Treatment Sessions

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment Session</strong></td>
<td>Q1-22</td>
<td>Q2-22</td>
<td>Q3-22</td>
</tr>
<tr>
<td>Total U.S. Treatment</td>
<td>$9,469</td>
<td>$11,295</td>
<td>$11,864</td>
</tr>
<tr>
<td>Session REVENUE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>YoY ∆</strong></td>
<td>-2%</td>
<td>5%</td>
<td>16%</td>
</tr>
<tr>
<td><strong>Average Revenue</strong></td>
<td>$9.9</td>
<td>$11.3</td>
<td>$11.4</td>
</tr>
<tr>
<td>per Active Site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>YoY ∆</strong></td>
<td>-6%</td>
<td>-6%</td>
<td>2%</td>
</tr>
</tbody>
</table>

(1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter)
## Revenue Growth Trends

<table>
<thead>
<tr>
<th>Revenue Growth Drivers (NSTS)</th>
<th>2021</th>
<th>YoY</th>
<th>2022</th>
<th>YoY</th>
<th>2023</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Full Year</td>
<td></td>
<td>Full Year</td>
<td></td>
<td>Full Year</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Act</td>
<td>Growth</td>
<td>Act</td>
<td>Growth</td>
<td>Act</td>
<td>Growth</td>
</tr>
<tr>
<td>Revenue Growth Drivers (NSTS)</td>
<td>35,113</td>
<td>20%</td>
<td>37,618</td>
<td>9%</td>
<td>43,936</td>
<td>17%</td>
</tr>
<tr>
<td>NeuroStar Capital</td>
<td>$9,760</td>
<td>-12%</td>
<td>$16,575</td>
<td>70%</td>
<td>$16,460</td>
<td>-1%</td>
</tr>
<tr>
<td>International</td>
<td>$1,865</td>
<td>8%</td>
<td>$1,800</td>
<td>-4%</td>
<td>$2,012</td>
<td>12%</td>
</tr>
<tr>
<td>Fixed Price Contracts</td>
<td>$6,820</td>
<td>23%</td>
<td>$7,460</td>
<td>9%</td>
<td>$6,960</td>
<td>-7%</td>
</tr>
<tr>
<td>All Other Revenue</td>
<td>$1,754</td>
<td>12%</td>
<td>$1,754</td>
<td>0%</td>
<td>$1,980</td>
<td>13%</td>
</tr>
<tr>
<td>Subtotal (non/low growth)</td>
<td>$20,199</td>
<td>1%</td>
<td>$27,588</td>
<td>37%</td>
<td>$27,411</td>
<td>-1%</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>$55,312</td>
<td>12%</td>
<td>$65,206</td>
<td>18%</td>
<td>$71,348</td>
<td>9%</td>
</tr>
</tbody>
</table>
## Supplemental Financial and Operating Information

<table>
<thead>
<tr>
<th>Revenue ($ thousands)</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
</tr>
<tr>
<td>Total U.S. NeuroStar Advanced Therapy System Revenues</td>
<td>$3,642</td>
<td>$4,382</td>
<td>$3,934</td>
<td>$4,616</td>
<td>$3,850</td>
</tr>
<tr>
<td>YoY Change</td>
<td>108%</td>
<td>70%</td>
<td>51%</td>
<td>64%</td>
<td>6%</td>
</tr>
<tr>
<td>Total U.S. Treatment Sessions Revenues</td>
<td>$9,469</td>
<td>$11,295</td>
<td>$11,864</td>
<td>$12,450</td>
<td>$10,643</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-2%</td>
<td>5%</td>
<td>16%</td>
<td>11%</td>
<td>12%</td>
</tr>
<tr>
<td>Total U.S. Other Revenues</td>
<td>$406</td>
<td>$455</td>
<td>$446</td>
<td>$447</td>
<td>$471</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-5%</td>
<td>6%</td>
<td>9%</td>
<td>-10%</td>
<td>16%</td>
</tr>
<tr>
<td>Total U.S. Revenues</td>
<td>$13,517</td>
<td>$16,132</td>
<td>$16,244</td>
<td>$17,513</td>
<td>$14,964</td>
</tr>
<tr>
<td>YoY Change</td>
<td>15%</td>
<td>17%</td>
<td>22%</td>
<td>20%</td>
<td>11%</td>
</tr>
<tr>
<td>Total International Revenues</td>
<td>$664</td>
<td>$198</td>
<td>$253</td>
<td>$686</td>
<td>$576</td>
</tr>
<tr>
<td>YoY Change</td>
<td>36%</td>
<td>-50%</td>
<td>-51%</td>
<td>47%</td>
<td>-13%</td>
</tr>
<tr>
<td>Total Revenues</td>
<td>$14,181</td>
<td>$16,329</td>
<td>$16,498</td>
<td>$16,199</td>
<td>$15,540</td>
</tr>
<tr>
<td>YoY Change</td>
<td>15%</td>
<td>15%</td>
<td>20%</td>
<td>21%</td>
<td>10%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U.S. Operating and Financial Metrics</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
</tr>
<tr>
<td>Total NeuroStar Systems</td>
<td>46</td>
<td>59</td>
<td>50</td>
<td>58</td>
<td>49</td>
</tr>
<tr>
<td>YoY Change</td>
<td>100%</td>
<td>64%</td>
<td>25%</td>
<td>21%</td>
<td>7%</td>
</tr>
<tr>
<td>Average Revenue Per Active Site ($)</td>
<td>$9,874</td>
<td>$11,280</td>
<td>$11,364</td>
<td>$11,517</td>
<td>$9,667</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-6%</td>
<td>-6%</td>
<td>2%</td>
<td>-5%</td>
<td>-2%</td>
</tr>
</tbody>
</table>

(1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)